News Headlines Article

Biotech bonanza lurks in healthcare reform bills
Los Angeles Times - Michael Hiltzik

The debate over healthcare reform is focused on such a small number of hot issues — should there be a public option, Medicare buy-in, government-paid mental health counseling for Sen. Lieberman? — that dozens of other questions are cruising under the radar. Here’s one worth a lot more attention than it has been getting: Is Congress poised to make a big payoff to biotech firms and their venture backers by hindering the entry of a new class of generic drugs into the marketplace?

Commands